Novel and nonpharmacologic approaches to cardio-protection in hypertension

Current Hypertension Reports

Volumn 16, Issue 5, 2014, Pages

  Donazzan, Luca ^a   Mahfoud, Felix ^a   Linz, Dominik ^a   Ewen, Sebastian ^a   Ukena, Christian ^a   Böhm, Michael ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Baroreceptor stimulation; Cardiac arrhythmias; Heart failure; Hypertension; Left ventricular hypertrophy; Renal sympathetic denervation; Resistant hypertension; Vascular remodeling

Indexed keywords

ADRENERGIC SYSTEM; BALLOON CATHETER; CLINICAL TRIAL (TOPIC); HEART INJURY; HEART PROTECTION; HEART RATE; HUMAN; HYPERTENSION; KIDNEY DENERVATION; METABOLIC SYNDROME X; MULTICENTER STUDY (TOPIC); PATIENT SELECTION; PRESSORECEPTOR; PRESSORECEPTOR REFLEX; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANIMAL; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY; PROCEDURES; SYMPATHECTOMY;

ANTIHYPERTENSIVE AGENT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; HUMANS; HYPERTENSION; PRESSORECEPTORS; SYMPATHECTOMY;

EID: 84899073267     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-014-0430-3     Document Type: Review

References (75)

1. •• Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34: 2159-219. This paper reports the most recent ESC/ESH Guidelines for the management of hypertension.
2. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117:e510-26.
3. Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith Jr SC, Crowley K, et al. Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. Eur Heart J. 2013;34:1204-14.
4. Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, et al. Clinical practice guidelines for the management of hypertension in the community a statement by the american society of hypertension and the international society of hypertension. J Hypertens. 2014;32:3-15. doi:10.1097/HJH.0000000000000065.
5. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively designed overviews of randomised trials. Lancet. 2003;362:1527-35. (Pubitemid 37410190)
6. Schlaich MP, Sobotka PA, Krum H, Lambert EA, Esler MD. Renal sympathetic nerve ablation for the treatment of uncontrolled hypertension. N Engl J Med. 2009;361:932-4.
7. Esler M. The 2009 Carl Ludwig Lecture: Pathophysiology of the human sympathetic nervous system in cardiovascular diseases: the transition from mechanisms to medical management. J Appl Physiol. 2010;108:227-37.
8. Wyss JM, Carlson SH. The role of the central nervous system in hypertension. Curr Hypertens Rep. 1999;1:246-53.
9. Dolezel S. Monoaminergic innervation of the arteries and veins of the kidney observed using fluorescence reaction. Folia Morphol. 1966;14:168-74.
10. Ljungqvist A, Wågermark J. The adrenergic innervation of intrarenal glomerular and extra-glomerular circulatory routes. Nephron. 1970;7:218-29.
11. Sobotka PA, Mahfoud F, Schlaich MP, Hoppe UC, Böhm M, Krum H. Sympatho-renal axis in chronic disease. Clin Res Cardiol. 2011;100:1049-57.
12. Redfield MM, Jacobsen SJ, Burnett Jr JC, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003;289:194-202. (Pubitemid 36068707)
13. Bombelli M, Facchetti R, Carugo S, Madotto F, Arenare F, Quarti-Trevano F, et al. Left ventricular hypertrophy increases cardiovascular risk independently of in-office and out-of office blood pressure values. J Hypertens. 2009;27:2458-64.
14. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics and prognosis. J Am Coll Cardiol. 2004;43:317-27. (Pubitemid 38167688)
15. Neuberger HR, Cacciatore A, Reil JC, Gräber S, Schäfers HJ, Ukena C, et al. Procollagen propeptides: serum markers for atrial fibrosis? Clin Res Cardiol. 2012;101:655-61.
16. Wickramasinghe SR, Patel VV. Local innervation and atrial fibrillation. Circulation. 2013;128:1566-75.
17. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369-429.
18. •• Linz D, Ukena C, Mahfoud F, Neuberger HR, Böhm M. Atrial Autonomic Innervation: A Target for Interventional Antiarrhythmic Therapy? J Am Coll Cardiol. 2013. doi:10.1016/j.jacc.2013.09.020. This paper describes the role of the autonomic nervous system on the development of a substrate for atrial fibrillation, and explores the potential antiarrhythmic and/or arrhythmogenic effect of modulation of the autonomic nervous system by renal sympathetic denervation, baroreceptor stimulation and other recent technologies.
19. Custodis F, Reil JC, Laufs U, Böhm M. Heart rate: a global target for cardiovascular disease and therapy along the cardiovascular disease continuum. J Cardiol. 2013;62:183-7.
20. Gillman MW, Kannel WB, Belanger A, D'Agostino RB. Influence of heart rate on mortality among persons with hypertension: the Framingham Study. Am Heart J. 1993;125:1148-54. (Pubitemid 23117352)
21. Al Bannay R, Böhm M, Husain A. Heart rate differentiates urgency and emergency in hypertensive crisis. Clin Res Cardiol. 2013;102:593-8.
22. Böhm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A, et al. SHIFT Investigators. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet. 2010;376:886-94.
23. Franke J, Wolter JS, Meme L, Keppler J, Tschierschke R, Katus HA, et al. Optimization of pharmacotherapy in chronic heart failure: is heart rate adequately addressed? Clin Res Cardiol. 2013;102:23-31.
24. Boutouyrie P, Tropeano AI, Asmar R, Gautier I, Benetos A, Lacolley P, et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension. 2002;39:10-5. (Pubitemid 34098081)
25. Huggett RJ, Scott EM, Gilbey SG, Stoker JB, Mackintosh AF, Mary DA. Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension. Circulation. 2003;108:3097-101. (Pubitemid 38031798)
26. Emerging Risk Factors C, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborativemeta-analysis of 102 prospective studies. Lancet. 2010;375:2215-22.
27. Floras J. Sympathetic nervous system activation in human heart failure: clinical implications of an updated model. J Am Coll Cardiol. 2009;54:375-85.
28. Sobotka P, Krum H, Böhm M, Francis D, Schlaich M. The role of renal denervation in the treatment of heart failure. Curr Cardiol Rep. 2012;14:285-92.
29. Triposkiadis F, Karayannis G, Giamouzis G, Skoularigis J, Louridas G, Butler J. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol. 2009;54:1747-62.
30. Petersson M, Friberg P, Eisenhofer G, Lambert G, Rundqvist B. Long-term outcome in relation to renal sympathetic activity in patients with chronic heart failure. Eur Heart J. 2005;26:906-13. (Pubitemid 40676571)
31. Page IH. The effect on renal efficiency of lowering arterial blood pressure in cases of essential hypertension and nephritis. J Clin Invest. 1934;13:909-15.
32. Page IH, Heuer GJ. The effect of renal denervation on the level of arterial blood pressure and renal function in essential hypertension. J Clin Invest. 1935;14:27-30.
33. Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension; results in 1,266 cases. J Am Med Assoc. 1953;152:1501-4.
34. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:1275-81.
35. •• Mahfoud F, Lüscher TF, Andersson B, Baumgartner I, Cifkova R, Dimario C, et al. Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur Heart J. 2013;34:2149-57. This paper is the Consensus statement of the European Society of Cardiology on percutaneous renal sympathetic denervation.
36. Vogel B, Kirchberger M, Zeier M, Stoll F, Meder B, Saure D, et al. Renal sympathetic denervation therapy in the real world: results from the Heidelberg registry. Clin Res Cardiol. 2014;103:117-24.
37. Ukena C, Cremers B, Ewen S, Böhm M, Mahfoud F. Response and non-response to renal denervation: who is the ideal candidate? EuroIntervention. 2013;9:R54-7.
38. •• Krum H, Schlaich MP, Böhm M, Mahfoud F, Rocha-Singh K, Katholi R, et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet. 2013. doi:10.1016/S0140-6736(13)62192-3. This paper reports the longest follow-up of the Symplicity HTN-1 study, which was the first study to assess the safety and efficacy of renal sympathetic denervation in humans.
39. •• Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 trial): a randomised controlled trial. Lancet. 2010;376:1903-9. This is the second randomised controlled trial investigating the effect of renal denervation with Symplicity catheter versus medical treatment alone in patients with resistant hypertension.
40. • Kandzari DE, Bhatt DL, Sobotka PA, O'Neill WW, Esler M, Flack JM, et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial. Clin Cardiol. 2012;35:528-35. This is the rationale and design of the first US trial on percutaneous renal sympathetic denervation with Symplicity catheter.
41. Worthley SG, Tsioufis CP, Worthley MI, Sinhal A, Chew DP, Meredith IT, et al. Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial. Eur Heart J. 2013;34:2132-40.
42. Mabin T, Sapoval M, Cabane V, Stemmett J, Iyer M. First experience with endovascular ultrasound renal denervation for the treatment of resistant hypertension. EuroIntervention. 2012;8:57-61.
43. Mahfoud F, Ukena C, Schmieder RE, Cremers B, Rump LC, Vonend O, et al. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation. 2013;128:132-40.
44. Schlaich MP, Schmieder RE, Bakris G, Blankestijn PJ, Böhm M, Campese VM, et al. International Expert Consensus Statement: Percutaneous Transluminal Renal Denervation for the Treatment of Resistant Hypertension. J Am Coll Cardiol. doi: 10.1016/j.jacc.2013.08.1616.
45. Ewen S, Mahfoud F, Linz D, Pöss J, Cremers B, Kindermann I, et al. Effects of renal sympathetic denervation on exercise blood pressure, heart rate, and capacity in patients with resistant hypertension. Hypertension. 2014. doi:10.1161/HYPERTENSIONAHA.113.01985.
46. •• Brandt MC, Mahfoud F, Reda S, Schirmer SH, Erdmann E, Böhm M, et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patientswith resistant hypertension. J Am Coll Cardiol. 2012;59:901-9. This paper reports the positive effect of renal denervation on left ventricular mass and diastolic function in patients with resistant hypertension.
47. Schirmer SH, Sayed MMYA, Reil J-C, Ukena C, Linz D, Kindermann M, et al. Improvements of left-ventricular hypertrophy and diastolic function following renal denervation - Effects beyond blood pressure and heart rate reduction. J Am Coll Cardiol. 2013. doi:10.1016/j.jacc.2013.10.073.
48. Brandt MC, Reda S, Mahfoud F, Lenski M, Böhm M, Hoppe UC. Effects of renal sympathetic denervation on arterial stiffness and central hemodynamics in patients with resistant hypertension. J Am Coll Cardiol. 2012;60:1956-65.
49. Hering D, Lambert EA, Marusic P, Ika-Sari C, Walton AS, Krum H, et al. Renal nerve ablation reduces augmentation index in patients with resistant hypertension. J Hypertens. 2013;31:1893-900.
50. Reil JC, Custodis F, Swedberg K, Komajda M, Borer JS, Ford I, et al. Heart rate reduction in cardiovascular disease and therapy. Clin Res Cardiol. 2011;100:11-9.
51. Hoke RS, Müller-Werdan U, Lautenschläger C, Werdan K, Ebelt H. Heart rate as an independent risk factor in patients with multiple organ dysfunction: a prospective, observational study. Clin Res Cardiol. 2012;101:139-47.
52. Fujita B, Franz M, Goebel B, Fritzenwanger M, Figulla HR, Kuethe F, et al. Prognostic relevance of heart rate at rest for survival and the quality of life in patients with dilated cardiomyopathy. Clin Res Cardiol. 2012;101:701-7.
53. •• Ukena C, Mahfoud F, Spies A, Kindermann I, Linz D, Cremers B, et al. Effects of renal sympathetic denervation on heart rate and atrioventricular conduction in patients with resistant hypertension. Int J Cardiol. 2013;167:2846-51. This paper reports the positive effect of renal denervation on heart rate in patients with resistant hypertension.
54. • Pokushalov E, Romanov A, Corbucci G, Artyomenko S, Baranova V, Turov A, et al. A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. J Am Coll Cardiol. 2012;60:1163-70. This is the first-in-man study evaluating the addiction of renal denervation to pulmonary vein ablation in atrial fibrillation treatment.
55. Linz D, Mahfoud F, Schotten U, Ukena C, Hohl M, Neuberger HR, et al. Renal sympathetic denervation provides ventricular rate control but does not prevent atrial electrical remodeling during atrial fibrillation. Hypertension. 2013;61:225-31.
56. Linz D, Mahfoud F, Schotten U, Ukena C, Neuberger HR, Wirth K, et al. Renal sympathetic denervation suppresses postapneic blood pressure rises and atrial fibrillation in a model for sleep apnea. Hypertension. 2012;60:172-8.
57. Linz D, Schotten U, Neuberger HR, Böhm M, Wirth K. Negative tracheal pressure during obstructive respiratory events promotes atrial fibrillation by vagal activation. Heart Rhythm. 2011;8:1436-43.
58. Linz D, Hohl M, Nickel A, Mahfoud F, Wagner M, Ewen S, et al. Effect of renal denervation on neurohumoral activation triggering atrial fibrillation in obstructive sleep apnea. Hypertension. 2013;62:767-74.
59. •• Ukena C, Bauer A, Mahfoud F, Schreieck J, Neuberger HR, Eick C, et al. Renal sympathetic denervation for treatment of electrical storm: first-in-man experience. Clin Res Cardiol. 2012;101:63-7. This is the first-in-man use of renal denervation to treat pharmacological and ablation persistent electrical storm.
60. Remo BF, Preminger M, Bradfield J, Mittal S, Boyle N, Gupta A, et al. Safety and efficacy of renal denervation as a novel treatment for ventricular tachycardia storm in patients with cardiomyopathy. Heart Rhythm. 2013. doi:10.1016/j.hrthm.2013.12.038.
61. Linz D, Wirth K, Ukena C, Mahfoud F, Pöss J, Linz B, et al. Renal denervation suppresses ventricular arrhythmias during acute ventricular ischemia in pigs. Heart Rhythm. 2013;10:1525-30.
62. •• Mahfoud F, Schlaich M, Kindermann I, Ukena C, Cremers B, Brandt MC, et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation. 2011;123:1940-6. This paper reports the potential pleiotropic effect of renal denervation on other organ systems, in particular on glucose metabolism.
63. Schlaich MP, Straznicky N, Grima M, Ika-Sari C, Dawood T, Mahfoud F, et al. Renal denervation: a potential new treatment modality for polycystic ovary syndrome? J Hypertens. 2011;29:991-6.
64. Witkowski A, Prejbisz A, Florczak E, Ka̧dziela J, Śliwiński P, Bieleń P, et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension. 2011;58:559-65.
65. Davies JE, Manisty CH, Petraco R, Barron AJ, Unsworth B, Mayet J, et al. First-in-man safety evaluation of renal denervation for chronic systolic heart failure: primary outcome from REACH-Pilot study. Int J Cardiol. 2013;162:189-92.
66. • Taborsky M, Lazarova ML, Vaclavik J. The effect of renal denervation in patients with advanced heart failure. Eur Heart J 2012;33:517 [Abstract Supplement]. This is the largest report of the safety and efficacy of renal denervation in heart failure patients.
67. Verloop WL, Beeftink MM, Nap A, Bots ML, Velthuis BK, Appelman YE, et al. Renal denervation in heart failure with normal left ventricular ejection fraction. Rationale and design of the DIASTOLE (DenervatIon of the renAl Sympathetic nerves in hearT failure with nOrmal Lv Ejection fraction) trial. Eur J Heart Fail. 2013;15:1429-37.
68. Bisognano JD, Bakris G, Nadim MK, Sanchez L, Kroon AA, Schafer J, et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension. J Am Coll Cardiol. 2011;58:765-73.
69. Heusser K, Tank J, Engeli S, Diedrich A, Menne J, Eckert S, et al. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function and blood pressure in hypertensive patients. Hypertension. 2010;55:619-26.
70. Schmidli J, Savolainen H, Eckstein F, Irwin E, Peters TK, Martin R, et al. Acute device-based blood pressure reduction: electrical activation of the carotid baroreflex in patients undergoing elective carotid surgery. Vascular. 2007;15:63-9. (Pubitemid 47026645)
71. Bakris GL, Nadim MK, Haller H, Lovett EG, Schafer JE, Bisognano JD. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the rheos pivotal trial. J Am Soc Hypertens. 2012;6:152-8.
72. Hoppe UC, Brandt MC, Wachter R, Beige J, Rump LC, Kroon AA, et al. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. J Am Soc Hypertens. 2012;6:270-6.
73. de Leeuw P, Gangahar D, Bach D, et al. Left ventricular reverse remodeling with chronic treatment of resistant hypertension using an implantable device: results from European and United States trials of the Rheos baroreflex hypertension therapy system. J Hypertens. 2008;26:S471.
74. Bisognano JD, Kaufman CL, Bach DS, Lovett EG, de Leeuw P, DEBuTHT, et al. Improved cardiac structure and function with chronic treatment using an implantable device in resistant hypertension: Results from European and United States trials of the Rheos system. J Am Coll Cardiol. 2011;57:1787-8.
75. Linz D, Mahfoud F, Schotten U, Ukena C, Neuberger HR, Wirth K, et al. Effects of electrical stimulation of carotid baroreflex and renal denervation on atrial electrophysiology. J Cardiovasc Electrophysiol. 2013;24:1028-33.